Relievant Medsystems has introduced next-generation Intracept Access Instruments for chronic vertebrogenic low back pain.
The instruments have been designed to provide predictable and accurate targeting of the basivertebral nerve (BVN) during the Intracept procedure.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Relievant’s minimally invasive Intracept procedure is claimed to be the only US Food and Drug Administration-approved treatment for chronic vertebrogenic low back pain.
The new Intracept Access instruments are said to offer predictable performance across several bone densities.
These instruments include Bevel and Diamond Introducers to facilitate consistent access with a depth marker for optimal positioning.
The Curved Cannula Assembly with J-Stylet enables true steerability for creating a predictable path to the BVN.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe Straight Stylet instrument helps extend or change the access path trajectory.
Designed to offer targeted radiofrequency energy, the IntraceptRF Probe now has a flexible shaft to enhance C-arm operating clearance.
Relievant Medsystems president and CEO Tyler Binney said: “Today, we are pleased to announce the launch of several new instruments offering greater control, precision and ease of use during the procedure.
“These next-generation Intracept Access Instruments are purpose-built to enhance BVN access and procedural efficiency while consistently delivering positive outcomes.”
More than 10,000 patients received treatment with Relievant’s same-day outpatient Intracept procedure that makes use of targeted radiofrequency energy for stopping the transmission of pain signals by BVN to the brain.
